Extended Data Fig. 4: Adjusted relapse-free survival of adjuvant patients treated as per TuPro recommendation versus non-TuPro subjects.
From: Feasibility of multiomics tumor profiling for guiding treatment of melanoma
a, Kaplan-Meier curve and adjusted relapse-free survival (RFS) in months, crude hazard ratio, adjusted hazard ratio and Log-rank P-value for the comparison between unmatched adjuvant treatments. b, Kaplan-Meier curve and adjusted RFS in months, crude hazard ratio, adjusted hazard ratio and Log-rank P-value for the comparison between matched adjuvant treatments.
